Literature DB >> 28966304

The Profile of MMP-9, MMP-9 mRNA Expression, -1562 C/T Polymorphism and Outcome in High-risk Traumatic Brain Injury: The Effect of Therapeutic Mild Hypothermia.

Eko Prasetyo1,2, Andi Asadul Islam1,3, Mochammad Hatta1,4, Djoko Widodo1,3, Ilhamjaya Pattelongi1,5.   

Abstract

The aim of this study was to investigate the effect of mild hypothermia therapy (34-36°C) and the alterations of matrix metalloproteinase-9 (MMP-9) in 20 patients with high-risk traumatic brain injury (TBI). The neurologic status and outcome were assessed using Full Outline of UnResponsiveness (FOUR) score and Glasgow Coma Scale (GCS). A prospective randomized control study involved patients with high-risk TBI (FOUR score ≤ 7). Patients were randomized into two groups, with and without mild hypothermia therapy which were investigated within 24 and 72 h. The MMP-9 level, MMP-9 mRNA expression and -1562 C/T polymorphism were estimated using enzyme-linked immune sorbent assay (ELISA), reversing transcription polymerase chain reaction (RT-PCR) and PCR-restriction fragment length polymorphism (PCR-RFLP). Different levels of these variables were compared in the two groups. In the hypothermia group, the expression of MMP-9 mRNA and the level of serum MMP-9 were significantly decreased (P < 0.05) within 72 h. There was a highly significant correlation between the expression of MMP-9 mRNA and the level of MMP-9 protein (R2 = 0.741, r = 0.861, P < 0.05). The study did not find in -1562 C/T polymorphism. The patients' outcome was improved significantly after mild hypothermia therapy (P < 0.05). The data obtained from this study show that mild hypothermia therapy down regulated the expression of MMP-9 mRNA, the MMP-9 protein level and increased the FOUR score and GCS in high-risk TBI patients within 72 h.

Entities:  

Keywords:  MMP-9; TBI; mild hypothermia therapy

Mesh:

Substances:

Year:  2017        PMID: 28966304      PMCID: PMC5709715          DOI: 10.2176/nmc.oa.2016-0322

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  43 in total

Review 1.  Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies.

Authors:  David J Loane; Alan I Faden
Journal:  Trends Pharmacol Sci       Date:  2010-10-29       Impact factor: 14.819

Review 2.  Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases.

Authors:  S Ye
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

3.  Validation of a new coma scale: The FOUR score.

Authors:  Eelco F M Wijdicks; William R Bamlet; Boby V Maramattom; Edward M Manno; Robyn L McClelland
Journal:  Ann Neurol       Date:  2005-10       Impact factor: 10.422

4.  Matrix metalloproteinase-9 expression and protein levels after fluid percussion injury in rats: the effect of injury severity and brain temperature.

Authors:  Feng Jia; Yao-hua Pan; Qing Mao; Yu-min Liang; Ji-yao Jiang
Journal:  J Neurotrauma       Date:  2010-06       Impact factor: 5.269

5.  Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals.

Authors:  Carmel M McEniery; Kevin M O'Shaughnessy; Patrick Harnett; Asif Arshad; Sharon Wallace; Kaisa Maki-Petaja; Barry McDonnell; Mike J Ashby; John Brown; John R Cockcroft; Ian B Wilkinson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-05-18       Impact factor: 8.311

6.  Matrix metalloproteinase-3 expression profile differentiates adaptive and maladaptive synaptic plasticity induced by traumatic brain injury.

Authors:  M C Falo; H L Fillmore; T M Reeves; L L Phillips
Journal:  J Neurosci Res       Date:  2006-09       Impact factor: 4.164

7.  Dymanics of matrix-metalloproteinase 9 after brain trauma--results of a pilot study.

Authors:  Martin Kolar; Jan Pachl; Helena Tomasova; Pavel Haninec
Journal:  Acta Neurochir Suppl       Date:  2008

8.  Mild hypothermia inhibits nuclear factor-kappaB translocation in experimental stroke.

Authors:  Hyung Soo Han; Murat Karabiyikoglu; Stephen Kelly; Raymond A Sobel; Midori A Yenari
Journal:  J Cereb Blood Flow Metab       Date:  2003-05       Impact factor: 6.200

9.  Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9.

Authors:  Taura L Barr; Lawrence L Latour; Kyung-Yul Lee; Timothy J Schaewe; Marie Luby; George S Chang; Ziad El-Zammar; Shaista Alam; John M Hallenbeck; Chelsea S Kidwell; Steven Warach
Journal:  Stroke       Date:  2009-12-24       Impact factor: 7.914

10.  Extracellular matrix proteins and tumor angiogenesis.

Authors:  N E Campbell; L Kellenberger; J Greenaway; R A Moorehead; N M Linnerth-Petrik; J Petrik
Journal:  J Oncol       Date:  2010-06-29       Impact factor: 4.375

View more
  1 in total

Review 1.  Doxorubicin induced immune abnormalities and inflammatory responses via HMGB1, HIF1-α and VEGF pathway in progressive of cardiovascular damage.

Authors:  Ahmad Syukri; Mochammad Hatta; Muzakkir Amir; Mohammad Saifur Rohman; Idar Mappangara; Cahyono Kaelan; Siti Wahyuni; Agussalim Bukhari; Ade Rifka Junita; Muhammad Reza Primaguna; Ressy Dwiyanti; Andini Febrianti
Journal:  Ann Med Surg (Lond)       Date:  2022-03-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.